Hyaluronidase
Hyaluronidase is an enzyme that breaks down hyaluronic acid, a naturally occurring polysaccharide in connective tissue. It is used as an adjunct to facilitate the absorption and dispersion of injected drugs, fluids, and to improve tissue permeability during subcutaneous or intramuscular administration.
Hyaluronidase is an enzyme that increases tissue permeability by breaking down hyaluronic acid, used to enhance drug absorption and treat extravasation injuries.
This medication carries a boxed (black box) warning — the strongest type of FDA warning. Review the full prescribing information before use.
Key facts at a glance
- ATC
- B06AA03
- RxNorm
- 5464
- Generic
- Hyaluronidase
- Class
- atc-b06
- Brands
- Rituxan Hycela, Herceptin Hylecta, Darzalex Faspro, Phesgo, Vyvgart Hytrulo, Ocrevus Zunovo, Tecentriq Hybreza, Opdivo Qvantig, Rybrevant Faspro, Amphadase, Vitrase, Hylenex
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- injection, prefilled syringe
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Dosage and administration
- Usual dose
- 2000 units per injection
- Maximum
- consult physician
- Frequency
- as needed for subcutaneous drug dispersion
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 75-200 units per injection
- Maximum
- consult physician
- Frequency
- as needed for subcutaneous drug dispersion
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 2000 units per injection
- Maximum
- consult physician
- Frequency
- as needed for subcutaneous drug dispersion
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
Overdose information
Special Populations
11 groupspregnancy
first trimesteravoid if possible
avoid use during pregnancy unless benefits outweigh risks
regular fetal monitoring
Use with caution and monitor for adverse effects.
pregnancy
second trimesteruse lowest effective dose
use only if benefits clearly outweigh risks
regular prenatal monitoring
Use with caution and monitor for adverse effects.
pregnancy
third trimesteruse lowest effective dose
use only if benefits outweigh potential risks
fetal monitoring in late pregnancy
Use with caution and monitor for adverse effects.
lactation
breastfeedingno specific adjustment
discontinue breastfeeding or express milk for 24 hours after treatment
monitor infant for adverse effects
geriatric
elderlyno specific adjustment needed
use standard dosing, monitor for hypersensitivity reactions
standard monitoring
pediatric_age
pediatrics under 2use with caution
use only under close medical supervision in children under 2 years
close monitoring for adverse reactions
Use with caution and monitor for adverse effects.
pediatric_age
pediatrics 2 to 18no specific adjustment
use standard pediatric dosing under medical supervision
standard pediatric monitoring
renal_impairment
mild to moderateno specific adjustment needed
standard dosing may be used
standard renal function monitoring
renal_impairment
severeuse with caution
use only if benefits outweigh risks
monitor renal function closely
Use with caution and monitor for adverse effects.
hepatic_impairment
mild to moderateno specific adjustment needed
standard dosing may be used
standard hepatic function monitoring
hepatic_impairment
severeuse with caution
use only if benefits outweigh risks
monitor hepatic function closely
Use with caution and monitor for adverse effects.
Statistics and clinical data
Drug class
Enzyme used to facilitate subcutaneous drug absorption
Mechanism of action
Enzymatic action enabling drug dispersion
Primary therapeutic use
Used in combination products to enhance drug absorption
FDA approved combination products
Including Rituxan Hycela, Herceptin HylectA, Darzalex Faspro, Phesgo, Vyvgart Hytrulo, Ocrevus Zunovo, Tecentriq Hybreza, Opdivo Qvantig, Rybrevant Faspro, Amphadase, Vitrase, Hylenex
Used to facilitate subcutaneous infusion of fluids and medications, treat extravasation injuries from IV injections, and as an adjunct in ophthalmic surgery. Also used off-label to improve absorption of subcutaneous injections and infusions.
Hyaluronidase temporarily depolymerizes hyaluronic acid in the extracellular matrix, increasing tissue permeability and allowing fluids to diffuse more easily through subcutaneous or intramuscular space.
Should not be injected into or around inflamed or infected areas, malignant tumors, or areas with reduced circulation. Allergic reactions are possible. Does not typically affect endogenous hyaluronic acid synthesis. Consult specific product labeling for dosing and administration instructions.
Contraindications
Conditions and patient states where this medication should be avoided or used with caution.
Do not use (1)
Known allergy to this medication or its components
Use caution (1)
Consult healthcare provider for benefits vs risks assessment
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy